Stockreport

Ono Announces Encouraging Efficacy Signals of ONO-2808, a S1P5 Receptor Agonist, in an interim analysis of Ongoing Phase 2 Clinical Trial in Patients with Multiple System Atrophy [Yahoo! F...

ONO PHARM CO UNSP/ADR  (OPHLY) 
NASDAQ:AMEX Investor Relations: ono.co.jp/eng/investor/index.html
PDF Phase 2 clinical trial was conducted in early multiple system atrophy patients within 5 years of symptom onset in Japan and the US Multiple system atrophy is a neurod [Read more]